Technology

Organoid is a miniature in vitro three-dimensional (3D) structure obtained from Adult Stem Cells (ACSs) or Pluripotent Stem Cells (PSCs). They possess self organized structures in an ordered design mimicing an organ’s natural form, which is why they are called ‘mini-organs’. Notably, organoids closely recapitulate particular organ functions and have more than one type of cell that is unique to that organ. (Lancaster M. & Knoblich J., Science, 2014; Clevers H., Cell, 2016; Lancester M. & Huch M., Dis. Model. Mech. 2019)

iPSC-derived endodermal hepatic organoid (eHEPO)

We developed a novel method to generate functional human liver organoids from Induced Pluripotent Cells (iPSC) and named it as endodermal hepatic organoid (eHEPO). It behaves as an in vitro model of the liver, creating the most realistic human-derived cell/tissue platform for healthy (normal) physiology and pathologies of liver (Akbari s., 2019)

Patient-derived cancer organoid (PDCO)

Patient-derived cancer organoids (PDCOs) are derived with high success rate from cancer tissue of individualized patients. Basic characteristics of primary tumors, including histological complexity and the genetic heterogeneity of human cancer, are recapitulated by PDCOs. Genetic modifications include copy number variation and mutation status remain even after several months of subsequent cultivation. By comparison to NGS based technologies, PDOs provide more clinically relevant, real-time modelling and in vitro testing opportunity that illustrates how individual patient’s own tumor cells respond to standard-of-care chemotherapies as well as targeted therapeutic agents. In addition, PDCOs can be extended in vitro over an extended period of time and used for high-throughput drug screening.

Select Sidearea

Technology

iPSC-derived endodermal hepatic organoid (eHEPO)

Patient-derived cancer organoid (PDCO)